BioFocus DPI Enhances High-Content Screening Capabilities
Product News Jan 06, 2009
BioFocus DPI announces that it has enhanced its high-content screening capabilities through the implementation of liquid handling instruments and advanced cell imaging devices.
As part of BioFocus DPI’s Intelligent Screening platform, high-content screening is paired with the use of disease-relevant assays in human primary cells to provide detailed information on the effect proteins and small molecules have on a disease phenotype. The technique is particularly useful for small molecule mechanism-of-action studies and disease pathway analyses used in target discovery campaigns.
With a newly acquired Caliper Zephyr liquid handling instrument and wide-field (Incell1000) and confocal (BD Pathway™) imaging devices, BioFocus DPI has increased both the throughput and quality of its high-content screening and imaging capabilities. This enables BioFocus DPI to further develop customized, biologically-relevant assays for partners’ discovery programs.
BioFocus DPI customers utilizing PrimePath™ and its proprietary adenoviral shRNA target discovery platform will benefit from BioFocus DPI’s expertise within a wide range of target classes and disease areas.
“Through continued investment in our high-content screening capabilities, we aim to meet the growing customer demand for information-rich small molecule and target screening,” said Kate Hilyard, VP Biological Sciences, BioFocus DPI. “These latest instruments extend our ability to monitor molecular events in complex, cell-based assays over long periods, thereby enriching our understanding of how and when a compound or protein plays a role in a disease process.”